145 related articles for article (PubMed ID: 19136344)
21. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
23. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Frances N; Claret L; Bruno R; Iliadis A
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1413-9. PubMed ID: 21476101
[TBL] [Abstract][Full Text] [Related]
24. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
Szetela AB; Gibson DE
Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
[TBL] [Abstract][Full Text] [Related]
25. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Mrozek E; Ramaswamy B; Young D; Rhoades CA; Kendra K; Allen J; Moore T; Hauger M; Watson H; Merriman N; Nadella P; Villalona-Calero M; Shapiro CL
Clin Breast Cancer; 2006 Jun; 7(2):141-5. PubMed ID: 16800973
[TBL] [Abstract][Full Text] [Related]
27. Role of capecitabine (Xeloda) in breast cancer.
Kaklamani VG; Gradishar WJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):137-44. PubMed ID: 12722873
[TBL] [Abstract][Full Text] [Related]
28. Implications of capecitabine (Xeloda) for cancer nursing practice.
Gerbrecht BM; Kangas T
Eur J Oncol Nurs; 2004; 8 Suppl 1():S63-71. PubMed ID: 15341883
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
31. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: A multicentre pilot study of the French geriatric oncology group (GERICO).
Rousseau F; Retornaz F; Joly F; Esterni B; Abadie-Lacourtoisie S; Fargeot P; Luporsi E; Servent V; Laguerre B; Brain E; Geneve J;
Crit Rev Oncol Hematol; 2010 Oct; 76(1):71-8. PubMed ID: 20356760
[TBL] [Abstract][Full Text] [Related]
32. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
33. Combination versus sequential single-agent therapy in metastatic breast cancer.
Miles D; von Minckwitz G; Seidman AD
Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
[TBL] [Abstract][Full Text] [Related]
34. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
36. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer.
Barrett-Lee P; Bidard FC; Pierga JY
Cancer Treat Rev; 2009 Nov; 35(7):582-9. PubMed ID: 19632050
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine dosing is not yet optimized for breast cancer.
Hudis C; Traina T; Norton L
Ann Oncol; 2010 Nov; 21(11):2291; author reply 2291-2. PubMed ID: 20501505
[No Abstract] [Full Text] [Related]
38. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Ajani J
Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
